

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
12 September 2002 (12.09.2002)

PCT

(10) International Publication Number
WO 02/070495 A1

(51) International Patent Classification⁷: **C07D 261/18**

(74) Agents: **BRAINARD, Charles, R.** et al.; Kenyon & Kenyon, One Broadway, New York, NY 10004 (US).

(21) International Application Number: **PCT/US02/06419**

(22) International Filing Date: **4 March 2002 (04.03.2002)**

(25) Filing Language: **English**

(26) Publication Language: **English**

(30) Priority Data:
60/273,172 2 March 2001 (02.03.2001) US
60/294,847 31 May 2001 (31.05.2001) US

(81) Designated States (*national*): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW.

(84) Designated States (*regional*): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

(71) Applicant (*for all designated States except BB, US*):
TEVA PHARMACEUTICAL INDUSTRIES LTD.
[IL/IL]; Basel Street 5, P.O. Box 3190, 49131 Petah Tiqva (IL).

(71) Applicant (*for BB only*): **TEVA PHARMACEUTICALS USA, INC.** [US/US]; 1090 Hordham Road, P.O. Box 1090, North Wales, PA 19454-1090 (US).

(72) Inventors; and

(75) Inventors/Applicants (*for US only*): **MENDELOVICI, Mariorara** [IL/IL]; Rechov Hadar 6/12, 76466 Rechovot (IL). **NIDAM, Tamar** [IL/IL]; Rechov Weizman 53/40, 56238 Yehud (IL).

Published:

- with international search report
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: **PROCESS FOR THE PREPARATION OF 1,2-BENZISOXAZOLE-3-ACETIC ACID**

(57) Abstract: The present invention provides a process for preparing 1,2-benzisoxazole-3-acetic acid, comprising the step of reacting 4-hydroxy-coumarin with hydroxyl-amine in the presence of a base. The present invention further provides a process for preparing a salt of benzisoxazole methane sulfonic acid, comprising the steps of 1) sulfonating 1,2-benzisoxazole-3-acetic acid using chlorosulfonic acid in a solvent mixture comprising methylene chloride and sodium hydroxide; and 2) isolating the salt of benzisoxazole methane sulfonic acid.

WO 02/070495 A1

PROCESS FOR THE PREPARATION OF 1,2-BENZISOXAZOLE-3-ACETIC ACID

CROSS-REFERENCE TO RELATED APPLICATIONS

5 This application claims the benefits under 35 U.S.C. §1.119(e) of Provisional Application Serial Nos. 60/273,172, filed March 2, 2001, and 60/294,847, filed May 31, 2001, the disclosure of which is incorporated by reference in its entirety herein.


10 FIELD OF THE INVENTION

The field of the invention relates to the preparation of 1,2-benzisoxazole-3-acetic acid. Within that field, the present invention relates more particularly to a method for preparing 1,2-benzisoxazole-3-acetic acid comprising the step of reacting 4-hydroxy-coumarin with a hydroxyl-amine in the presence of a base.

15

BACKGROUND OF THE INVENTION

Zonisamide is currently available as an anti-epileptic agent which possesses anti-convulant and anti-neurotoxic effects. Zonisamide is also known as 1,2-
20 benzisoxazole-3-methane sulfonamide or 3-(sulfamylmethyl)-1,2-benzisoxazole. It has the following chemical formula:




25

The preparation of zonisamide is described in Japanese Pat. No. 53-77057 and Yakugaku Zasshi, 116(7), 533-47, 1996, both of which are incorporated herein by
30 reference. These references teach a synthesis process of zonisamide that involves 4 or 5-steps, starting from 4-hydroxy-coumarin (4-HC). The synthesis of zonisamide occurs via the intermediates: namely, 1,2-benzisoxazole-3-acetic acid (BOA) and the sodium salt of benzisoxazole methane sulfonic acid (BOS-Na).


Many synthetic routes for preparing zonisamide have been described in the literature. One of the synthetic routes for preparing zonisamide is described in U.S. Pat. No. 4,172,896 and Japanese Pat. No. 53-77057 to Dainippon. This particular synthetic route starts from 1,2-benzisoxazole-3-bromo-methane (zonisamide-bromide). The zonisamide-bromide is converted to 1,2-benzisoxazole-3-methane-sulfonic acid sodium salt (BOS-Na) in the reaction with sodium sulfite as is shown in the following scheme 1:

Scheme 1



Zonisamide-bromide is prepared according to the literature (Chem. Pharm. Bull., (Tokyo), 24, 632, 1976) by the bromination reaction of 1,2-benzisoxazole-3-acetic acid (BOA). BOA is prepared by Posner reaction (T. Posner, Chem. Ber., 42, 2523, 0913, T. Posner, and R. Hess, Chem. Ber., 46, 3816, 1913, M. Gianella, F. Gualtieri, C. Melchiorre and A. Orlandoni, Chem. Therap., 1972, 2, 127) and starts from 4-hydroxy-coumarin in the reaction with metallic sodium as shown in the following scheme 2:

Scheme 2




The Posner reaction for BOA preparation involves the use of metallic sodium. When metallic sodium is used in alcoholic solution, BOA is not the sole reaction product and the side-reaction product, O-hydroxy-acetophenone-oxime, is obtained in about 30%.

The high percentage of the side reaction products as well as the difficulty of using the aforementioned process on an industrial scale due to the use of metallic sodium render said process unfavorable, and thus the need for an improved process for preparing BOA and BOS-Na intermediates remains.

According to Dainnison in the patent Japanese Pat. No. 53-77057, an alternative synthetic route for preparing zonisamide starts from 4-hydroxy-coumarin may occur via the same intermediates BOA and BOS-Na as shown in the following scheme 3:

Scheme 3



1,2-benzisoxazole-3-acetic acid (BOA), the product of the initial step after reacting 4-HC with NH_2OH (scheme 3), is converted to the intermediate BOS-Na in the sulfonation reaction with ClSO_3H /dioxane in ethylene chloride at room temperature for about three hours followed by about 6 hours heating at about 50°C . After the reaction is complete, water and NaOH are added and the product is isolated as sodium salt (BOS-Na) by evaporation of the aqueous layer. BOA and BOS-Na are the intermediates in the zonisamide preparation according to both synthetic schemes. All the cited references are incorporated by reference in their entireties herein.

OBJECTS AND SUMMARY OF THE INVENTION

An object of the present invention is to provide an improved process for preparing a salt of BOS (e.g., BOS-Na) with higher purity and lesser side-products.

5 Another object of the present invention is to provide an improved process for preparing a salt of BOS (e.g., BOS-Na) as an intermediate for the preparation of 1,2-benzisoxazole-3-methane sulfonamide (i.e., zonisamide).

10 Another object of the present invention is to provide an improved process for preparing a salt of BOS (e.g., BOS-Na) in which the sulfonation of BOA occurs in a solvent of methylene chloride (instead of ethylene chloride).

15 Another object of the present invention is to prepare 1,2-benzisoxazole-3-acetic acid (BOA) without the use of metallic sodium; and thus the process of this invention is substantially less hazardous.

20 Another object of the present invention is to prevent the formation of side-products, e.g., oximes; and thus, significantly increasing the yield of BOA, and substantially reducing the burden of removing the oxime side-product with ether, which by itself is hazardous.

25 Another yet object of the present invention is to prepare BOA or salts of BOS (e.g., BOS-Na); which are thereafter converted to 1,2-benzisoxazole-3-methane sulfonamide (i.e., zonisamide).

The present invention provides a process for preparing 1,2-benzisoxazole-3-acetic acid (BOA), comprising the step of reacting 4-hydroxy-coumarin (4-HC) with hydroxyl-amine in the presence of a base.

30 In a preferred embodiment, the base is selected from the group consisting of carbonate salts, aqueous ammonia, and organic bases. In another preferred embodiment, the carbonate salt is selected from the group of sodium carbonate (Na_2CO_3) and potassium carbonate (K_2CO_3). In another preferred embodiment, the organic base is an amine. More preferably, the amine is selected from the group
35 consisting of triethyl-amine, tributyl-amine, and diethyl-amine.

In another preferred embodiment, the present invention provides a process for preparing 1,2-benzisoxazole-3-acetic acid (BOA), comprising the step of reacting 4-hydroxy-coumarin (4-HC) with hydroxyl-amine in the presence of a base, said process occurs in the presence of an alcoholic solvent.

5

Preferably, the alcoholic solvent is a lower alcohol. More preferably, the lower alcohol is selected from the group consisting of ethanol, methanol, n-butanol, iso-propyl-alcohol, iso-butanol, amyl-alcohol, and iso-amyl-alcohol.

10

In another preferred embodiment, the present invention provides a process for preparing 1,2-benzisoxazole-3-acetic acid (BOA), comprising the step of reacting 4-hydroxy-coumarin (4-HC) with hydroxyl-amine in the presence of a base and an alcoholic solution, wherein said process occurs at a temperature between room temperature and boiling point of the alcoholic solvent.

15

More preferably, the temperature of the reaction is between about 40°C and about 60°C.

The present invention also provides an improved process of preparing a salt of
20 benzisoxazole methane sulfonic acid, comprising the steps of: 1) sulfonating 1,2-benzisoxazole-3-acetic acid (BOA) using chlorosulfonic acid and dioxane in methylene chloride and sodium hydroxide solvents; and 2) isolating the salt of benzisoxazole methane sulfonic acid.

25

The present invention provides an improved process for preparing a salt of BOS (e.g., BOS-Na) in which the product is isolated by precipitation from an aqueous solvent. Preferably, the precipitation is performed by salting-out with, e.g., sodium chloride. More preferably, the precipitation is performed by salting-out and cooling.

30

In another preferred embodiment, the salt of BOS (e.g., BOS-Na) is isolated by evaporation.

Preferably, the salt of BOS may be isolated as BOS-Ba or BOS-Ca.

In another preferred embodiment, the preparation of the BOS-salt (e.g., BOS-Na) occurs at about 40 °C, preferably at about 55⁰C. Preferably, the preparation of the BOS-salt is performed for a time duration of about 4 hours. More preferably, the preparation is performed for about 3, about 3.5 and about 5 hours.

According to the present invention, the reaction was improved as the reaction (for converting BOA to BOS-Na) is faster when methylene chloride is used. In other words, the reaction rate is faster when the solvent of the reaction is changed from ethylene chloride to methylene chloride.

DETAILED DESCRIPTION OF THE INVENTION

As used herein, the following abbreviations are used: 1,2-benzisoxazole-3-acetic acid (BOA); benzisoxazole methane sulfonic acid (BOS); sodium salt of benzisoxazole methane sulfonic acid (BOS-Na); barium salt of benzisoxazole methane sulfonic acid (BOS-Ba); calcium salt of benzisoxazole methane sulfonic acid (BOS-Ca), chlorosulfonic acid (ClSO₃H); "organic base" refers to a base of carbon compounds; "room temperatuer" refers to ambient temperature of about 20⁰C to about 25⁰C.

As disclosed in the present application, when methylene chloride was used to repeat the procedure as disclosed in Japanese Patent 53-77057, it was found that the reaction was substantially faster. The reaction was completed in about 12-17 hours of heating when ethylene chloride was used. In contrast, the reaction was completed in only about 3-5 hours at about 40⁰C when methylene chloride was used (*See*, the exp. # 2337 and exp. # 2356 in the Table 1).

According to the present invention, the process was further improved as it provides an alterative isolation procedure. It is known that the product (BOS-Na) can be isolated by evaporation of an aqueous phase. The present invention also provides two alternatives in which the product is precipitated from water which can be induced by the following ways; for example:

a) BOS-Na may be isolated from water by precipitation by salting-out; e.g., with sodium chloride (i.e., NaCl) and cooling; and

b) BOS-Ba or BOS-Ca may be isolated based on their low solubility, and can be quantitatively precipitated from water. Separation of BOS as the barium (Ba) or calcium (Ca) salt facilitates industrial scale preparation of this intermediate. Once the salt precipitates, it may be washed with water to reduce the inorganic salt content.

A product contaminated with inorganic salts is usually more hygroscopic than the pure compound; and, its use is problematic in the POCl₃ reaction.

EXAMPLES

The present invention is described below in detail with reference to examples.

The present invention is by no means restricted to these specific examples. The experiments are summarized as followed.

Table 1 BOS Preparation Experiments

Exp.	Solvent	Temp. (°C)	Reaction time (hours)	Isolation of the product		Reference
				Salt type	Procedure	
# 2337	C ₂ H ₄ Cl ₂ (ethylene chloride)	55°C	12	Na	Evaporation of the water solution	Process as in 53-77057
# 2356	CH ₂ Cl ₂ (methylene chloride)	40°C	4	Na	Evaporation of the water solution	Present proc
# 2361	CH ₂ Cl ₂	40°C	5	Na	Precipitation from water by salting-out with NaCl	Present proc
# 2362	CH ₂ Cl ₂	40°C	3	Ca	Precipitation from water	Present proc
# 2363	CH ₂ Cl ₂	40°C	3.5	Ba	Precipitation from water	Present proc

Table 2 % BOA Yield and % Side-Products Under Various Experimental Conditions

Exp. No.	Solvent	Base	BOA Yield (%)	% Oxime	% Unreacted 4-HC	Reference
1	Ethanol	Na	68.3	19.8		1
2	Ethanol-water	Na-acetate	48.7	30.8		2
3*	Ethanol	Na ₂ CO ₃	82	0.2	17.5	Present procedure
4*	Methanol	Na ₂ CO ₃	87.5	1.1	7.5	Present procedure
5*	n-BuOH	Na ₂ CO ₃	98	0.9	1	Present procedure
6*	n-BuOH	K ₂ CO ₃	82.9	17		Present procedure

* % represents area of HPLC chromatogram of respective products over total area

5 Reference 1: *Chem. Pharm. Bull.*, (Tokyo), 24, 632, 1976
T. Posner and R. Hess, Ber., 46, 3816, 1913

Reference 2: G. Casini, F. Gualtieri, M.L. Stern, *J. Hererocyclic Chem.*, 2, 385, 1965

10 Experimental procedures

Example 1 Reaction with Na₂CO₃/n-BuOH

4-Hydroxy-coumarin (10 grams), was added to the mixture of hydroxyl-amine hydrochloride (15 grams) and sodium carbonate (23 grams) in n-BuOH (100 mL). The reaction mixture was than heated to reflux and the reflux was maintained for
15 about 13 hours. The reaction mixture was concentrated on rotavapor and the residue was washed with water and dried at about 60°C. The product weighs about 8.56 grams (yield: about 80% w/w).

Example 2 Reaction with K₂CO₃/n-BuOH

20 4-Hydroxy-coumarin (10 grams) was added to the mixture of hydroxyl-amine hydrochloride (15 grams) and potassium carbonate (9.30 grams) in n-BuOH (100 mL). The reaction mixture was heated at reflux for about 20 hours.

The HPLC analysis of the reaction mixture shows the following composition:
25 about 80% product BOA (w/w), about 15% oxime (w/w) and about 5% 4-HC (w/w).

Example 3 Reaction with Et₃N/MeOH

4-Hydroxy-coumarin (10 grams), hydroxyl-amine hydrochloride (15 grams) and triethyl-amine (22 grams) in MeOH (50 mL) were heated at reflux for about 1.5 hours. The residue obtained after evaporation to dryness was dissolved in aqueous
5 NaHCO₃ and extracted with ether. After acidification of the aqueous phase the product was isolated by filtration and washed with water. The yield is about 73% (w/w).

Example 4 Reaction with Et₂NH/MeOH

10 4-Hydroxy-coumarin (100 grams), hydroxyl-amine hydrochloride (150 grams) and diethyl-amine (160 grams) in MeOH (500 mL) were heated at reflux for about 1 hour. The reaction mixture was evaporated to dryness and the solid was dissolved in aqueous. NaHCO₃ and extracted with ether; from the aqueous phase the product was obtained upon acidification with HCl. The solid was washed with water and dried on
15 oven at about 60°C. The solid weighs about 99.82 grams (yield: about 93% w/w).

It is contemplated that various modifications of the described modes of carrying out the invention will be apparent to those skilled in the art without departing from the scope and spirit of the invention.

WHAT IS CLAIMED IS:

1. A process for preparing 1,2-benzisoxazole-3-acetic acid, comprising the step of reacting 4-hydroxy-coumarin with hydroxyl-amine in the presence of a base.
2. The process according to claim 1, wherein the base is selected from the group consisting of carbonate salts, aqueous ammonia, and organic bases.
3. The process according to claim 2, wherein the carbonate salt is selected from the group consisting of sodium carbonate and potassium carbonate.
4. The process according to claim 2, wherein the organic base is an amine.
5. The process according to claim 4, wherein the amine is selected from the group consisting of triethyl-amine, tributyl-amine, and diethyl-amine.
6. The process according to claim 1, wherein the process is performed in the presence of an alcohol.
7. The process according to claim 6, wherein the alcohol is a lower alcohol.
8. The process according to claim 7, wherein the lower alcohol is selected from the group consisting of ethanol, methanol, n-butanol, iso-propyl-alcohol, iso-butanol, amyl-alcohol, and iso-amyl alcohol.
9. The process according to claim 6, wherein the process is performed at a temperature between room temperature and boiling point of the alcohol.
10. The process according to claim 9, wherein the process is performed at a temperature between about 40°C and about 60°C.
11. A process of preparing a salt of benzisoxazole methane sulfonic acid comprising the steps of: 1) sulfonating 1,2-benzisoxazole-3-acetic acid using chlorosulfonic acid and dioxane in a solvent mixture comprising methylene

chloride and sodium hydroxide; and 2) isolating the salt of benzisoxazole methane sulfonic acid.

- 5 12. The process according to claim 11, wherein the isolating step is performed by evaporating the solvent mixture after the sulfonating step.
13. The process according to claim 11, wherein the isolating step is performed by salting-out with sodium chloride.
- 10 14. The process according to 13, further comprising the step of cooling after the step of salting-out.
15. The process according to claim 11, wherein the salt of benzisoxazole methane sulfonic acid is selected from the group consisting of sodium, calcium, and
15 barium.
16. The process according to claim 11, wherein the preparation of benzisoxazole methane sulfonic acid is performed at a temperature of about 40°C and for a time of about 4 hours.
- 20 17. The process according to claim 11, wherein the preparation of benzisoxazole methane sulfonic acid is performed at a temperature of about 40°C and a time of about 5 hours.
18. The process according to claim 11, wherein the preparation of benzisoxazole methane sulfonic acid is performed at a temperature of about 40°C and a time of about 3 hours.
- 25 19. The process according to claim 11, wherein the preparation of benzisoxazole methane sulfonic acid is performed at a temperature of about 55°C and a time of about 3.5 hours.
- 30 20. The process according to claim 1, wherein the 1,2-benzisoxazole-3-acetic acid is thereafter converted to 1,2-benzisoxazole-3-methane sulfonamide.

21. The process according to claim 11, wherein the benzisoxazole methane sulfonic acid is thereafter converted to 1,2-benzisoxazole-3-methane sulfonamide.

5

22. 1,2-benzisoxazole-3-methane sulfonamide prepared in accordance with the process of claim 1.

10

23. 1,2-benzisoxazole-3-methane sulfonamide prepared in accordance with the process of claim 11.

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US02/06419

A. CLASSIFICATION OF SUBJECT MATTER

IPC(7) : C07D 261/18

US CL : 548/241

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

U.S. : 548/241

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched
STN-CAS ONLINEElectronic data base consulted during the international search (name of data base and, where practicable, search terms used)
EAST/WEST**C. DOCUMENTS CONSIDERED TO BE RELEVANT**

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X --- Y	Database CASREACT, Accession No.110:192693, THOUREL, et al, Synthesis of 1,2-benzisooxazole-3-acetic acid-.alpha.-14C and -.beta.-14C acid J. Labelled Compd. Radiopharm. 1988, Vol. 25, No. 11, pages 1235-44.	1-2 and 6-10 ----- 4-5
X --- Y	US 00 5,484,763 A (Wepplo) 16 January 1996 (16.01.1996), column 40, flow diagram XL, lines 55-column 41, line 20, see entire document..	1-10 ----- 1-10
X --- Y	JP 53-77057 (DAINNIPON) 07 August 1978 (07.08.1978), column 5, scheme (b) and (c), see entire document..	11-12, 15-23 ----- 13-14, 15-23

☐ Further documents are listed in the continuation of Box C.☐ See patent family annex.

Special categories of cited documents:	
* "A" document defining the general state of the art which is not considered to be of particular relevance	"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
"E" earlier application or patent published on or after the international filing date	"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
"O" document referring to an oral disclosure, use, exhibition or other means	"&" document member of the same patent family
"P" document published prior to the international filing date but later than the priority date claimed	

Date of the actual completion of the international search

09 July 2002 (09.07.2002)

Date of mailing of the international search report

20 AUG 2002

Name and mailing address of the ISA/US

Commissioner of Patents and Trademarks
Box PCT
Washington, D.C. 20231

Facsimile No. (703)305-3230

Authorized officer

Hallerie Bell-Harris for
Andrea D Small

Telephone No. (703) 308-1235

Form PCT/ISA/210 (second sheet) (July 1998)